July 18, 2017 — There are now over 5,800 Risperdal lawsuits pending in the Philadelphia Court of Common Pleas accusing Johnson & Johnson of failing to warn about the risk of gynecomastia.
Gynecomastia is a disfiguring side effect of Risperdal in which young boys grow female breast tissue. Treatment usually involves surgery.
Johnson & Johnson is facing thousands of lawsuits nationwide, but a growing number are now centralized at the state-level in Philadelphia, where the number of lawsuits skyrocketed by 185% since January.
In 2017, the Risperdal mass-tort in Philadelphia doubled in size with over 3,600 new lawsuits, and it is on track to triple in size by 2018, according to the The Legal Intelligencer.
Johnson & Johnson is accused of of illegally marketing Risperdal for unapproved “off-label” uses in children. As a result, many children grew female breasts and required surgery. Lawyers say the drug-maker told doctors the risk of gynecomastia was only about 2% when they knew the actual risk for young boys on Risperdal was about 5%.
Juries have returned several multi-million dollar verdicts in favor of boys who were diagnosed with gynecomastia. In July 2016, a jury awarded $70 million to a 5 year-old boy from Tenneseee who grew breasts. In 2015, there were three verdicts for $500,000, $1.75 million, and $2.5 million. Other cases ended in confidential settlements.
Do I have a Risperdal Lawsuit?
The Schmidt Firm, PLLC is currently accepting Risperdal induced injury cases in all 50 states. If you or somebody you know has been diagnosed with gynecomastia, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.
Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.